Evaluation of new drugs and combinations in gynecologic tumors and cancer cell lines with the ATP-cell viability assay.
Untch
M
M
Klinik und Poliklinik für Frauenheilkunde im Klinikum Grosshadern, Ludwig-Maximilians-Universität, München, BRD.
Sevin
B U
BU
D000255:Adenosine Triphosphate; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D002470:Cell Survival; D002945:Cisplatin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D015251:Epirubicin; D004317:Doxorubicin; D000255:Adenosine Triphosphate; D017239:Paclitaxel; D002945:Cisplatin